JSR Life Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

JSR Life Sciences, founded in 2017 and headquartered in Leuven, Belgium, is a specialized service provider in the advanced therapeutics space. It functions as a hybrid entity, offering both contract research (CRO) services via Crown Bioscience and contract development and manufacturing (CDMO) services via KBI Biopharma, targeting the cell and gene therapy sectors. The company also develops and sells proprietary bioprocessing tools, such as its Amsphere A+ Protein A chromatography resin, positioning itself across the entire biopharmaceutical value chain. Its model is designed to support clients from discovery through to commercial-scale production of complex biological medicines.

Cell TherapyGene Therapy

Technology Platform

Integrated CRO (Crown Bioscience) and CDMO (KBI Biopharma) service platforms for biopharmaceutical and advanced therapy development and manufacturing. Also develops proprietary bioprocessing products like the Amsphere A+ Protein A chromatography resin.

Opportunities

The company is positioned to capitalize on the rapid growth of the cell and gene therapy market, where outsourcing of complex development and manufacturing is essential.

Its integrated CRO/CDMO model and proprietary bioprocessing products create multiple revenue streams and client lock-in opportunities.

Risk Factors

Faces intense competition from larger, global CROs/CDMOs and is exposed to cyclical funding downturns in the biotech sector.

Operational risks include potential for errors in client projects, and the capital-intensive nature of CDMO expansion requires sustained investment.

Competitive Landscape

Operates in a highly competitive market with major players like Lonza, Catalent, Thermo Fisher Scientific, and Samsung Biologics in the CDMO space, and numerous specialized CROs. Differentiation is sought through integrated services, focus on advanced therapies, and proprietary product offerings.

More companies in Small Molecule Drugs →More companies in Belgium →